Cantex Pharmaceuticals Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Private

  • Employees
  • 2

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 1

Cantex Pharmaceuticals General Information

Description

Developer of biopharmaceutical technologies designed to improve the treatment of cancers and other life-threatening disorders. The company's biopharmaceutical technologies modify and repurpose existing drugs and create novel, proprietary, safe and effective therapeutics, enabling physicians to enhance the safety and effectiveness of existing cancer treatments.

Contact Information

Website
www.cantex.com
Formerly Known As
ParinGenix, KRCT Therapeutics, Paringenix Inc
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 1792 Bell Tower Lane
  • Weston, FL 33326
  • United States
+1 (954)
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 1792 Bell Tower Lane
  • Weston, FL 33326
  • United States
+1 (954)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cantex Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Secondary Transaction - Private 01-Sep-2022 Completed Clinical Trials - Phase 2
8. Later Stage VC (Series D) 24-Nov-2014 Completed Clinical Trials - Phase 2
7. Secondary Transaction - Private Completed Clinical Trials - Phase 2
6. Later Stage VC (Series C) 23-Apr-2014 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series C) 04-Aug-2010 Completed Clinical Trials - Phase 2
4. Grant 31-Dec-2009 Completed Clinical Trials - Phase 2
3. Later Stage VC 13-Aug-2007 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series B) 25-Aug-2006 $5.92M $9.5M Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A) 12-Aug-2002 $3.62M $3.62M Completed Startup
To view Cantex Pharmaceuticals’s complete valuation and funding history, request access »

Cantex Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D
Series C
Series B
Series A2 1,359,060 $0.001000 8% $1.49 $1.49 1x $1.49 0.48%
Series A1 1,600,000 $0.001000 8% $1 $1 1x $1 0.56%
To view Cantex Pharmaceuticals’s complete cap table history, request access »

Cantex Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of biopharmaceutical technologies designed to improve the treatment of cancers and other life-threatening diso
Pharmaceuticals
Weston, FL
2 As of 2021

Nijmegen, Netherlands
 

Abingdon, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cantex Pharmaceuticals Competitors (93)

One of Cantex Pharmaceuticals’s 93 competitors is Byondis, a Corporation company based in Nijmegen, Netherlands.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Byondis Corporation Nijmegen, Netherlands
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Agios Pharmaceuticals Formerly VC-backed Cambridge, MA
ArriVent Biopharma Formerly VC-backed Newtown Square, PA
Nektar Therapeutics Formerly VC-backed San Francisco, CA
You’re viewing 5 of 93 competitors. Get the full list »

Cantex Pharmaceuticals Patents

Cantex Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-11648235-B1 Treatment of glioblastoma Active 30-Dec-2022
US-20240216333-A1 Treatment of glioblastoma Inactive 30-Dec-2022
US-10322096-B2 Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage forms Active 26-Oct-2016
US-20200038345-A1 Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage forms Active 26-Oct-2016
CA-3041857-A1 Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage forms Pending 26-Oct-2016 A61K31/145
To view Cantex Pharmaceuticals’s complete patent history, request access »

Cantex Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cantex Pharmaceuticals Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Qualifying Therapeutic Discovery Project Not-For-Profit Venture Capital
To view Cantex Pharmaceuticals’s complete investors history, request access »

Cantex Pharmaceuticals FAQs

  • When was Cantex Pharmaceuticals founded?

    Cantex Pharmaceuticals was founded in 2002.

  • Where is Cantex Pharmaceuticals headquartered?

    Cantex Pharmaceuticals is headquartered in Weston, FL.

  • What is the size of Cantex Pharmaceuticals?

    Cantex Pharmaceuticals has 2 total employees.

  • What industry is Cantex Pharmaceuticals in?

    Cantex Pharmaceuticals’s primary industry is Pharmaceuticals.

  • Is Cantex Pharmaceuticals a private or public company?

    Cantex Pharmaceuticals is a Private company.

  • What is Cantex Pharmaceuticals’s current revenue?

    The current revenue for Cantex Pharmaceuticals is .

  • How much funding has Cantex Pharmaceuticals raised over time?

    Cantex Pharmaceuticals has raised $51.3M.

  • Who are Cantex Pharmaceuticals’s investors?

    Qualifying Therapeutic Discovery Project has invested in Cantex Pharmaceuticals.

  • Who are Cantex Pharmaceuticals’s competitors?

    Byondis, Adaptimmune Therapeutics, Agios Pharmaceuticals, ArriVent Biopharma, and Nektar Therapeutics are some of the 93 competitors of Cantex Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »